TG Therapeutics Stock Climbs After The Bell: Here's Why

Benzinga01-14

TG Therapeutics, Inc. (NASDAQ:TGTX) shares climbed in Tuesday’s extended trading after the company released its preliminary fourth quarter revenue estimates and provided an optimistic outlook for 2026. Here’s a look at the details.

TGTX stock is climbing. See the chart and price action here.

TG Therapeutics said it expects Briumvi U.S. net product revenue to be approximately $182 million and $594 million for the fourth quarter and full year of 2025, respectively, with total global full year 2025 revenue of approximately $616 million.

The company is targeting full-year 2026 total global revenue of approximately $875 to 900 million, including Briumvi U.S. net product revenue of approximately $825 to 850 million.

“Briumvi continued to deliver strong commercial performance in 2025, reinforcing our confidence in the multi-billion dollar opportunity for Briumvi. With significant market share capture since launch, we believe TG Therapeutics is well positioned to drive long-term revenue growth and cash flow,” said CEO Michael Weiss.

TGTX Price Action: TG Therapeutics shares were up 6.60% at $29.71 in Tuesday’s extended trading, according to data from Benzinga Pro.

Photo: Shutterstock

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603653448?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-14 06:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603653448","market":"hk","top_or_hot":-1,"title":"TG Therapeutics Stock Climbs After The Bell: Here's Why","media":"Benzinga","content":"<html><body><p><strong>TG <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, Inc. </strong>(NASDAQ:TGTX) shares climbed in Tuesday’s extended trading after the company released its preliminary fourth quarter revenue estimates and provided an optimistic outlook for 2026. Here’s a look at the details. </p>\n<ul>\n<li><strong>TGTX stock is climbing. See the chart and price action here. </strong></li>\n</ul>\n<p>TG Therapeutics said it expects Briumvi U.S. net product revenue to be approximately $182 million and $594 million for the fourth quarter and full year of 2025, respectively, with total global full year 2025 revenue of approximately $616 million. </p>\n<p>The company is targeting full-year 2026 total global revenue of approximately $875 to 900 million, including Briumvi U.S. net product revenue of approximately $825 to 850 million.</p>\n<p>“Briumvi continued to deliver strong commercial performance in 2025, reinforcing our confidence in the multi-billion dollar opportunity for Briumvi. With significant market share capture since launch, we believe TG Therapeutics is well positioned to drive long-term revenue growth and cash flow,” said CEO <strong>Michael Weiss.</strong> </p>\n<p><strong>TGTX Price Action:</strong> TG Therapeutics shares were up 6.60% at $29.71 in Tuesday’s extended trading, according to data from Benzinga Pro. </p>\n<p><em>Photo: Shutterstock</em></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TG Therapeutics Stock Climbs After The Bell: Here's Why</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTG Therapeutics Stock Climbs After The Bell: Here's Why\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2026-01-14 06:05</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong>TG <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, Inc. </strong>(NASDAQ:TGTX) shares climbed in Tuesday’s extended trading after the company released its preliminary fourth quarter revenue estimates and provided an optimistic outlook for 2026. Here’s a look at the details. </p>\n<ul>\n<li><strong>TGTX stock is climbing. See the chart and price action here. </strong></li>\n</ul>\n<p>TG Therapeutics said it expects Briumvi U.S. net product revenue to be approximately $182 million and $594 million for the fourth quarter and full year of 2025, respectively, with total global full year 2025 revenue of approximately $616 million. </p>\n<p>The company is targeting full-year 2026 total global revenue of approximately $875 to 900 million, including Briumvi U.S. net product revenue of approximately $825 to 850 million.</p>\n<p>“Briumvi continued to deliver strong commercial performance in 2025, reinforcing our confidence in the multi-billion dollar opportunity for Briumvi. With significant market share capture since launch, we believe TG Therapeutics is well positioned to drive long-term revenue growth and cash flow,” said CEO <strong>Michael Weiss.</strong> </p>\n<p><strong>TGTX Price Action:</strong> TG Therapeutics shares were up 6.60% at $29.71 in Tuesday’s extended trading, according to data from Benzinga Pro. </p>\n<p><em>Photo: Shutterstock</em></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TG","symbol_name":"特里迪加","start_time":0,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/01/49893865/tg-therapeutics-stock-climbs-after-the-bell-heres-why","article_id":"2603653448","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603653448","pubTimestamp":1768341952,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"TG Therapeutics releases its preliminary Q4 revenue estimates and provides an optimistic outlook for 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TG":"特里迪加","BK4588":"碎股","BK4585":"ETF&股票定投概念","TGTX":"TG Therapeutics Inc.","BK4139":"生物科技","BK4153":"铝","BK4090":"商品化工"},"translate_title":"TG Therapeutics股价盘后攀升：原因如下","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TG":1.5,"TGTX":1.5},"content_text":"TG Therapeutics, Inc. (NASDAQ:TGTX) shares climbed in Tuesday’s extended trading after the company released its preliminary fourth quarter revenue estimates and provided an optimistic outlook for 2026. Here’s a look at the details. \n\nTGTX stock is climbing. See the chart and price action here. \n\nTG Therapeutics said it expects Briumvi U.S. net product revenue to be approximately $182 million and $594 million for the fourth quarter and full year of 2025, respectively, with total global full year 2025 revenue of approximately $616 million. \nThe company is targeting full-year 2026 total global revenue of approximately $875 to 900 million, including Briumvi U.S. net product revenue of approximately $825 to 850 million.\n“Briumvi continued to deliver strong commercial performance in 2025, reinforcing our confidence in the multi-billion dollar opportunity for Briumvi. With significant market share capture since launch, we believe TG Therapeutics is well positioned to drive long-term revenue growth and cash flow,” said CEO Michael Weiss. \nTGTX Price Action: TG Therapeutics shares were up 6.60% at $29.71 in Tuesday’s extended trading, according to data from Benzinga Pro. \nPhoto: Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603653448","isCrawlerRequest":true}